$53.70
1.09% today
Nasdaq, Sep 25, 03:48 pm CET
ISIN
US30063P1057
Symbol
EXAS

Exact Sciences Corporation Stock News

Positive
Seeking Alpha
about 5 hours ago
Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver strong revenue growth, while Cancerguard expands its addressable market into multi-cancer early detection. Risks include regulatory hurdles, payer coverage, and competition from Guardant and Grail, but ...
Neutral
Business Wire
3 days ago
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage people 45 and older to get screened for colorectal cancer—the nation's second leading cause of cancer-related death.1 Best known for his roles in cult classics like Scream and Scooby-Doo, Lillard i...
Neutral
Business Wire
8 days ago
DALLAS--(BUSINESS WIRE)--Healthmine and Exact Sciences partner to increase colorectal cancer screening rates through at-home testing and health plan incentives.
Neutral
Business Wire
15 days ago
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help de...
Neutral
Seeking Alpha
16 days ago
Exact Sciences Corporation (NASDAQ:EXAS ) Baird 2025 Global Healthcare Conference September 9, 2025 10:50 AM EDT Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Raj Pudipeddi - EVP, Chief Growth Officer Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior...
Neutral
Seeking Alpha
22 days ago
Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good afternoon.
Neutral
Business Wire
about one month ago
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.
Neutral
Business Wire
about one month ago
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conf...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today